company background image
CHEMM logo

ChemoMetec CPSE:CHEMM Stock Report

Last Price

DKK 479.40

Market Cap

DKK 8.3b

7D

4.6%

1Y

68.1%

Updated

20 Apr, 2025

Data

Company Financials +

CHEMM Stock Overview

Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. More details

CHEMM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for CHEMM from our risk checks.

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

ChemoMetec A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for ChemoMetec
Historical stock prices
Current Share PriceDKK 479.40
52 Week HighDKK 616.00
52 Week LowDKK 281.20
Beta1.6
1 Month Change-10.22%
3 Month Change-5.44%
1 Year Change68.09%
3 Year Change-42.17%
5 Year Change54.90%
Change since IPO2,079.09%

Recent News & Updates

Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is Unlikely

Apr 06
Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is Unlikely

ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 08
ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent Results

Recent updates

Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is Unlikely

Apr 06
Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is Unlikely

ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 08
ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent Results

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Dec 12
What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Nov 09
ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Sep 18
We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Jul 29
What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

Jul 29
Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Jul 03
What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

Apr 15
Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

Mar 01
What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Mar 01
What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 08
Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Dec 21
Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Nov 15
Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 17
ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

Sep 15
A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

Jun 20
At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

Jun 01
With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

Jan 24
Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Oct 26
If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Oct 05
Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

Jul 18
Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

Shareholder Returns

CHEMMDK Life SciencesDK Market
7D4.6%6.4%2.3%
1Y68.1%-12.4%-34.1%

Return vs Industry: CHEMM exceeded the Danish Life Sciences industry which returned -12.4% over the past year.

Return vs Market: CHEMM exceeded the Danish Market which returned -34.1% over the past year.

Price Volatility

Is CHEMM's price volatile compared to industry and market?
CHEMM volatility
CHEMM Average Weekly Movement7.2%
Life Sciences Industry Average Movement7.2%
Market Average Movement5.8%
10% most volatile stocks in DK Market9.9%
10% least volatile stocks in DK Market3.6%

Stable Share Price: CHEMM has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: CHEMM's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997184Martin Behrenschemometec.com

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer.

ChemoMetec A/S Fundamentals Summary

How do ChemoMetec's earnings and revenue compare to its market cap?
CHEMM fundamental statistics
Market capDKK 8.34b
Earnings (TTM)DKK 169.08m
Revenue (TTM)DKK 459.54m

49.3x

P/E Ratio

18.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CHEMM income statement (TTM)
RevenueDKK 459.54m
Cost of RevenueDKK 41.04m
Gross ProfitDKK 418.51m
Other ExpensesDKK 249.43m
EarningsDKK 169.08m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 07, 2025

Earnings per share (EPS)9.72
Gross Margin91.07%
Net Profit Margin36.79%
Debt/Equity Ratio0.2%

How did CHEMM perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

41%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/20 17:28
End of Day Share Price 2025/04/16 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ChemoMetec A/S is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kallum TitchmarshBofA Global Research
null nullDanske Bank
Simon LarssonDanske Bank